Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

BACKGROUND: Exenatide once weekly (QW) is a glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes. Safety and tolerability are key considerations in treatment selection. This analysis examines the safety and tolerability profile of exenatide QW, other approved GLP-1...

Descripción completa

Detalles Bibliográficos
Autores principales: MacConell, Leigh, Gurney, Kate, Malloy, Jaret, Zhou, Ming, Kolterman, Orville
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445788/
https://www.ncbi.nlm.nih.gov/pubmed/26056482
http://dx.doi.org/10.2147/DMSO.S77290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445788/
https://www.ncbi.nlm.nih.gov/pubmed/26056482
http://dx.doi.org/10.2147/DMSO.S77290

Ejemplares similares